Bristol-Myers Squibb Company (BMY - Free Report) is a New York-based major producer and distributor of pharmaceuticals and other healthcare related products. The company’s key oncology products include Opdivo, Sprycel, Yervoy and Empliciti. Other than oncology, the company is focused on immunology and cardiovascular drugs like Orencia and Eliquis. It also markets drugs for HBV and HCV like Baraclude and Daklinza. The company’s virology portfolio comprises products like Reyataz and the Sustiva franchise.

Bristol-Myers is also active on partnership front and pursue strategic acquisitions across therapeutic areas including immunoscience, oncology, fibrosis and genetically defined diseases.

However, like many of its peers, Bristol-Myers is facing generic competition for several of its key products. Moreover, its HIV and HCV businesses are under competitive pressure. In this scenario, investor focus remains on company’s high-profile immuno-oncology drug, Opdivo, apart from the usual top-and bottom-line numbers.

Bristol-Myers has a mixed record of earnings surprises in the recent quarters. The company’s earnings surpassed expectations in three of the last four quarters, with an average positive surprise of 4.23%

Currently, Bristol-Myers has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: Bristol-Myers beats on first-quarter 2018 earnings. The company reported EPS of 94 cents while our consensus called for EPS of 84 cents.

Revenues: Moreover, revenues were above expectations. Bristol-Myers posted revenues of $5.19 billion, compared to our consensus estimate of $5.18 billion.

2018 Guidance: Bristol-Myers increased its earnings outlook for 2018. The company now expects earnings in the range of $3.35 to $3.45 per share (previously $3.15 to $3.30). The Zacks Consensus Estimate for earnings stands at $3.22 per share.

Pre-Market Trading: Shares are up 0.5% in pre-market trading.

Key Stats: The FDA approved a combination regimen of Opdivo plus Yervoy for the treatment of intermediate- and poor-risk advanced renal cell carcinoma in treatment naïve patients. Moreover, a new 480 mg dosing schedule for Opdivo every four weeks was approved in both the United States and Europe.

Bristol-Myers Squibb Company Price and EPS Surprise

Bristol-Myers Squibb Company Price and EPS Surprise | Bristol-Myers Squibb Company Quote